135 related articles for article (PubMed ID: 340032)
61. A trial of razoxane (ICRF-159) in patients with prior therapy for Hodgkin's lymphoma.
Corder MP; McFadden DB; Bell SJ
Cancer; 1984 Oct; 54(8):1496-8. PubMed ID: 6383594
[TBL] [Abstract][Full Text] [Related]
62. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas.
Miller TP; Jones SE; Alberts DS; Mackel C
Invest New Drugs; 1984; 2(1):75-7. PubMed ID: 6469502
[TBL] [Abstract][Full Text] [Related]
63. Phase II study of cytarabine in Hodgkin's disease. The EORTC Lymphoma Cooperative Group.
Thomas J; de Pauw B; Hagenbeek A; Somers R; Carde P; Tirelli U; Duez N
Eur J Cancer; 1992; 28A(4-5):857-9. PubMed ID: 1524908
[TBL] [Abstract][Full Text] [Related]
64. Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia.
Kucuk O; Kilton L; Wade JL; Blough R; Benson AB
Am J Clin Oncol; 2000 Aug; 23(4):379-83. PubMed ID: 10955868
[TBL] [Abstract][Full Text] [Related]
65. Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study.
Thigpen JT; Blessing JA; Homesley HD; Lewis GC
Gynecol Oncol; 1986 Mar; 23(3):358-63. PubMed ID: 3754234
[TBL] [Abstract][Full Text] [Related]
66. Comparison of chlorambucil and streptonigrin (NSC-45383) in the treatment of malignant lymphomas.
Kaung DT; Wittington RM; Spencer H; Patno ME
Cancer; 1969 Jun; 23(6):1280-3. PubMed ID: 4890442
[No Abstract] [Full Text] [Related]
67. Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
Hanson KH; Crowley J; Salmon SE; Keppen M; Braun TJ; Bonnet JD
Anticancer Drugs; 1991 Jun; 2(3):247-50. PubMed ID: 1802018
[TBL] [Abstract][Full Text] [Related]
68. I, i and IT antigens in lymphoma, Hodgkin's disease and multiple myeloma.
Joshi SR; Advani SH; Bhatia HM
Indian J Med Res; 1980 Nov; 72():715-20. PubMed ID: 7203574
[No Abstract] [Full Text] [Related]
69. Hematologic malignancies-sixth European congress. 26-28 February 2010, Cannes, France .
Buske C
IDrugs; 2010 May; 13(5):300-3. PubMed ID: 20432183
[TBL] [Abstract][Full Text] [Related]
70. Epirubicin in non-Hodgkin's lymphomas.
Lopez M; Perno CF; Di Lauro L; Papaldo P; Ganzina F; Di Pietro N
Am J Clin Oncol; 1985 Apr; 8(2):151-3. PubMed ID: 3869431
[TBL] [Abstract][Full Text] [Related]
71. Do anthracyclines have a role in the therapy of multiple myeloma?
Rödjer S; Nilsson B; Westin J;
Hematol J; 2000; 1(6):422-6. PubMed ID: 11920223
[TBL] [Abstract][Full Text] [Related]
72. Evaluation of uracil mustard in children with Hodgkin's disease, lymphosarcoma, and soft tissue sarcoma.
Berry DH; Sutow WW; Vietti TJ; Fernbach DJ; Sullivan MP; Haggard ME; Lane DM
J Clin Pharmacol New Drugs; 1972 Apr; 12(4):169-73. PubMed ID: 4553449
[No Abstract] [Full Text] [Related]
73. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma.
Lenhard RE; Oken MM; Barnes JM; Humphrey RL; Glick JH; Silverstein MN
Cancer; 1984 Apr; 53(7):1456-60. PubMed ID: 6697291
[TBL] [Abstract][Full Text] [Related]
74. Effect of treatment with thymustimulin (Tp-1) on T and B cells in lymphoproliferative disorders.
Pontiggia P; Ogier C; Follini GD
Blut; 1983 Sep; 47(3):153-6. PubMed ID: 6603885
[TBL] [Abstract][Full Text] [Related]
75. VM26 in malignant hematological diseases. A phase II study.
Tirelli U; Carbone A; Franchin G; Galligioni E; Veronesi A; Trovo MG; Volpe R; Tumolo S; Grigoletto E
Cancer Chemother Pharmacol; 1982; 7(2-3):173-4. PubMed ID: 6952964
[TBL] [Abstract][Full Text] [Related]
76. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
[TBL] [Abstract][Full Text] [Related]
77. Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.
Louie AC; Gallagher JG; Sikora K; Levy R; Rosenberg SA; Merigan TC
Blood; 1981 Oct; 58(4):712-8. PubMed ID: 6168319
[TBL] [Abstract][Full Text] [Related]
78. Continuous treatment of non-Hodgkin's malignant lymphoma with prednimustine (Leo 1031).
Håkansson L; Könyves I; Lindberg LG; Möller T
Oncology; 1978; 35(3):103-6. PubMed ID: 673314
[TBL] [Abstract][Full Text] [Related]
79. Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study.
Durie BG; Crowley J; Coltman CA; Chapman RA; Balcerzk SP; Bonnet JD; Lipschitz DA; Stephens RL; Cheson BD
Invest New Drugs; 1991 Nov; 9(4):329-31. PubMed ID: 1804807
[No Abstract] [Full Text] [Related]
80. A phase II study of neocarzinostatin (NSC 157365) in malignant hepatoma. An Eastern Cooperative Oncology Group pilot study.
Falkson G; Von Hoff D; Klaassen D; Du Plessis H; Van Der Merwe CF; Van Der Merwe AM; Carbone PP
Cancer Chemother Pharmacol; 1980; 4(1):33-6. PubMed ID: 6244904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
